OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the stock.

Several other research firms also recently commented on OCX. Stephens reiterated an “equal weight” rating and issued a $4.00 price objective on shares of OncoCyte in a research note on Wednesday, April 17th. Benchmark restated a “speculative buy” rating and set a $5.00 target price on shares of OncoCyte in a research report on Monday, April 15th. Finally, Needham & Company LLC increased their target price on OncoCyte from $3.60 to $4.25 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $4.06.

OncoCyte Trading Up 2.4 %

OncoCyte stock opened at $2.55 on Tuesday. OncoCyte has a 12 month low of $2.08 and a 12 month high of $5.88. The business’s 50 day simple moving average is $2.86 and its 200 day simple moving average is $3.01.

Insider Transactions at OncoCyte

In other news, major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of the firm’s stock in a transaction dated Thursday, April 11th. The shares were purchased at an average price of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the acquisition, the insider now owns 4,929,066 shares in the company, valued at approximately $14,392,872.72. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Andrew Arno purchased 33,898 shares of the firm’s stock in a transaction dated Thursday, April 11th. The shares were purchased at an average price of $2.95 per share, with a total value of $99,999.10. Following the completion of the acquisition, the director now owns 69,054 shares in the company, valued at approximately $203,709.30. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of OncoCyte stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average cost of $2.92 per share, for a total transaction of $7,066,400.00. Following the purchase, the insider now owns 4,929,066 shares of the company’s stock, valued at $14,392,872.72. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 2,457,288 shares of company stock valued at $7,176,400. 1.94% of the stock is currently owned by company insiders.

OncoCyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.